Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.

Abstract:

:The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride channel localized primarily at the apical surfaces of epithelial cells lining airway, gut and exocrine glands, where it is responsible for transepithelial salt and water transport. Several human diseases are associated with an altered channel function of CFTR. Cystic fibrosis (CF) is caused by the loss or dysfunction of CFTR-channel activity resulting from the mutations on the gene; whereas enterotoxin-induced secretory diarrheas are caused by the hyperactivation of CFTR channel function. CFTR is a validated target for drug development to treat these diseases. Significant progress has been made in developing CFTR modulator therapy by means of high-throughput screening followed by hit-to-lead optimization. Several oral administrated investigational drugs are currently being evaluated in clinical trials for CF. Also importantly, new ideas and methodologies are emerging. Targeting CFTR-containing macromolecular complexes is one such novel approach.

journal_name

Future Med Chem

authors

Zhang W,Fujii N,Naren AP

doi

10.4155/fmc.12.1

subject

Has Abstract

pub_date

2012-03-01 00:00:00

pages

329-45

issue

3

eissn

1756-8919

issn

1756-8927

journal_volume

4

pub_type

杂志文章,评审
  • DYRK1A inhibition as potential treatment for Alzheimer's disease.

    abstract::In total, 47,500,000 people worldwide are affected by dementia and this number is estimated to double by 2030 and triple within 2050 resulting in a huge burden on public health. Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia, accounting for 60-70% of all the ca...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0013

    authors: Stotani S,Giordanetto F,Medda F

    更新日期:2016-04-01 00:00:00

  • Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs.

    abstract::Acetyl-CoA carboxylase (ACC), a critical enzyme in the regulation of fatty acid synthesis and metabolism, has emerged as an attractive target for a plethora of emerging diseases, such as diabetes mellitus, nonalcoholic fatty liver disease, cancer, bacterial infections and so on. With decades of efforts in medicinal ch...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0312

    authors: Wu X,Huang T

    更新日期:2020-03-01 00:00:00

  • Rho kinase as a target for cerebral vascular disorders.

    abstract::The development of novel pharmaceutical treatments for disorders of the cerebral vasculature is a serious unmet medical need. These vascular disorders are typified by a disruption in the delicate Rho signaling equilibrium within the blood vessel wall. In particular, Rho kinase overactivation in the smooth muscle and e...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.45

    authors: Bond LM,Sellers JR,McKerracher L

    更新日期:2015-01-01 00:00:00

  • Collaboration versus outsourcing: the need to think outside the box.

    abstract::As has been widely reviewed elsewhere, the pharmaceutical industry is experiencing an 'innovation deficit' as evidenced by the decline in new chemical entity output. This decline, compounded by increased costs and regulatory requirements highlights the need to significantly revise strategic options across the drug-dis...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.11.160

    authors: Robertson GM,Mayr LM

    更新日期:2011-12-01 00:00:00

  • Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.

    abstract::Bromodomain and extra-terminal domain (BET) protein family plays an important role in regulating gene transcription preferentially at super-enhancer regions and has been involved with several types of cancers as a candidate. Up to now, there are 16 pan-BET inhibitors in clinical trials, however, most of them have unde...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0264

    authors: Yang Y,Wu Z,Chen P,Zheng P,Zhang H,Zhou J

    更新日期:2020-09-01 00:00:00

  • Analysis of structure-based virtual screening studies and characterization of identified active compounds.

    abstract::Structure-based virtual screening makes explicit or implicit use of 3D target structure information to detect novel active compounds. Results of nearly 300 currently available original applications have been analyzed to characterize the state-of-the-art in this field. Compound selection from docking calculations is mu...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.12.18

    authors: Ripphausen P,Stumpfe D,Bajorath J

    更新日期:2012-04-01 00:00:00

  • Exploring the roles of protein kinases using chemical genetics.

    abstract::The protein kinase superfamily is one of the most important families of enzymes in molecular biology. Protein kinases typically catalyze the transfer of the γ-phosphate from ATP to a protein substrate (a highly ubiquitous cellular reaction), thereby controlling key areas of cell regulation. Deregulation of protein kin...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.09.50

    authors: Elphick LM,Lee SE,Anderson AA,Child ES,Bonnac L,Gouverneur V,Mann DJ

    更新日期:2009-10-01 00:00:00

  • 3D-Lab: a collaborative web-based platform for molecular modeling.

    abstract:AIM:The use of 3D information has shown impact in numerous applications in drug design. However, it is often under-utilized and traditionally limited to specialists. We want to change that, and present an approach making 3D information and molecular modeling accessible and easy-to-use 'for the people'. METHODOLOGY/RES...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2016-0081

    authors: Grebner C,Norrby M,Enström J,Nilsson I,Hogner A,Henriksson J,Westin J,Faramarzi F,Werner P,Boström J

    更新日期:2016-09-01 00:00:00

  • Structural and functional insight of New Delhi Metallo β-lactamase-1 variants.

    abstract::New Delhi Metallo β-lactamase-1 (NDM-1) is a member of the Metallo-β-lactamase family, capable of catalyzing the hydrolysis of all β-lactam antibiotics. The rapid dissemination of NDM producers, 'superbugs', has become a worldwide concern to health workers. Seventeen different variants of NDM have been reported so far...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0143

    authors: Khan S,Ali A,Khan AU

    更新日期:2018-01-01 00:00:00

  • Structural and functional regulation of lactate dehydrogenase-A in cancer.

    abstract::Dysregulated metabolism is one of the hallmarks of cancer. Under normal physiological conditions, ATP is primarily generated by oxidative phosphorylation. Cancers commonly undergo a dramatic shift toward glycolysis, despite the presence of oxygen. This phenomenon is known as the Warburg effect, and requires the activi...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0287

    authors: Woodford MR,Chen VZ,Backe SJ,Bratslavsky G,Mollapour M

    更新日期:2020-03-01 00:00:00

  • Confident application of a global human liver microsomal activity QSAR.

    abstract::Metabolic stability is an important property of drug candidates and pharmaceutical companies often have human liver microsomal (HLM) data for a large number of molecules, enabling development of global quantitative structure-activity relationship models. RESULTS:This study describes a strategy for building a global H...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0323

    authors: Stålring J,Sohlenius-Sternbeck AK,Terelius Y,Parkes K

    更新日期:2018-07-01 00:00:00

  • Replacing sulfa drugs with novel DHPS inhibitors.

    abstract::More research effort needs to be invested in antimicrobial drug development to address the increasing threat of multidrug-resistant organisms. The enzyme DHPS has been a validated drug target for over 70 years as the target for the highly successful sulfa drugs. The use of sulfa drugs has been compromised by the wides...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.13.97

    authors: Hammoudeh DI,Zhao Y,White SW,Lee RE

    更新日期:2013-07-01 00:00:00

  • PEGylation and its impact on the design of new protein-based medicines.

    abstract::PEGylation is the covalent conjugation of PEG to therapeutic molecules. Protein PEGylation is a clinically proven approach for extending the circulation half-life and reducing the immunogenicity of protein therapeutics. Most clinically used PEGylated proteins are heterogeneous mixtures of PEG positional isomers conjug...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.14.125

    authors: Ginn C,Khalili H,Lever R,Brocchini S

    更新日期:2014-01-01 00:00:00

  • Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries.

    abstract::The emergence of antimicrobial resistance has created a need for the development of novel antibacterial therapies to treat infection. Natural products that exhibit antibacterial activity offer validated starting points for library generation, and the authors report here that small molecule mimics of tetramate-containi...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.15.97

    authors: Jeong YC,Moloney MG

    更新日期:2015-01-01 00:00:00

  • Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease.

    abstract:AIM:Alzheimer's disease is a progressive and neurodegenerative disorder of the CNS, affecting elderly people. The current pharmacological approach is based on the improvement of cholinergic neurotransmission by inhibiting acetylcholinesterase (AChE) with AChE inhibitors. The disease is also characterized by the acceler...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0201

    authors: de Almeida JR,Figueiro M,Almeida WP,de Paula da Silva CHT

    更新日期:2018-05-01 00:00:00

  • Benford's law in medicinal chemistry: Implications for drug design.

    abstract::Aim: The explosion of data based technology has accelerated pattern mining. However, it is clear that quality and bias of data impacts all machine learning and modeling. Results & methodology: A technique is presented for using the distribution of first significant digits of medicinal chemistry features: logP, logS, a...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0006

    authors: García-Sosa AT

    更新日期:2019-09-01 00:00:00

  • Computational insight into the anticholinesterase activities and electronic properties of physostigmine analogs.

    abstract::Aim: Alzheimer's disease (AD) is known to be themajor cause of dementia among the elderly. The structural properties and binding interactions of the AD drug physostigmine (-)-phy, and its analogues (-)-hex and (-)-phe and (+)-phe, were examined, as well as their impact on the conformational changes of two different AD...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0421

    authors: Adeniyi AA,Conradie J

    更新日期:2019-08-01 00:00:00

  • Sialic acid as a target for the development of novel antiangiogenic strategies.

    abstract::Sialic acid is associated with glycoproteins and gangliosides of eukaryotic cells. It regulates various molecular interactions, being implicated in inflammation and cancer, where its expression is regulated by sialyltransferases and sialidases. Angiogenesis, the formation of new capillaries, takes place during inflamm...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0298

    authors: Chiodelli P,Urbinati C,Paiardi G,Monti E,Rusnati M

    更新日期:2018-12-01 00:00:00

  • Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.

    abstract::Mycobacterium tuberculosis (Mtb) acquires non-heme iron through salicylate-derived siderophores termed mycobactins whereas heme iron is obtained through a cascade of heme uptake proteins. Three proteins are proposed to mediate Mtb heme iron uptake, a secreted heme transporter (Rv0203), and MmpL3 and MmpL11, which are ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.109

    authors: Owens CP,Chim N,Goulding CW

    更新日期:2013-08-01 00:00:00

  • Nanoformulations for glioblastoma multiforme: a new hope for treatment.

    abstract::Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, associated with a high mortality rate and a survival of between 12 and 15 months after diagnosis. Due to current treatment limitations involving surgery, radiotherapy and chemotherapy with temozolamide, there is a high rate of tr...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0521

    authors: Ortiz R,Cabeza L,Perazzoli G,Jimenez-Lopez J,García-Pinel B,Melguizo C,Prados J

    更新日期:2019-09-01 00:00:00

  • Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights.

    abstract::This perspective explores the origins of both fluorine and medicinal chemistry a century ago and traces the early history of the intersection of these areas and the subsequent roles that fluorine has played in advancing medicinal innovations and diagnoses during the past 60 years. The overview highlights remarkable br...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.09.65

    authors: Filler R,Saha R

    更新日期:2009-08-01 00:00:00

  • Making way for suppressing the FGF19/FGFR4 axis in cancer.

    abstract::FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0099

    authors: Prieto-Dominguez N,Shull AY,Teng Y

    更新日期:2018-10-01 00:00:00

  • Butterfly structure: a scaffold of therapeutic importance.

    abstract::Graphical abstract [Formula: see text]. ...

    journal_title:Future medicinal chemistry

    pub_type: 社论

    doi:10.4155/fmc-2019-0313

    authors: Choudhary S,Silakari O

    更新日期:2020-02-01 00:00:00

  • Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B.

    abstract::Aim: To encapsulate amphotericin B (AmB) with reduced toxicity and comparable activity. Results & methodology: The α-linolenic acid (ALA)-modified monomethoxy polyethylene glycol-g-PEI-g-ALA conjugate was employed to prepare AmB-loaded micelles (AmB-M). In vitro activity and release behavior of AmB-M were investigated...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0580

    authors: Xu H,Teng F,Zhou F,Zhu L,Wen Y,Feng R,Song Z

    更新日期:2019-10-01 00:00:00

  • Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition.

    abstract:AIM:Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among prev...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0308

    authors: Comsa E,Nguyen KA,Loghin F,Boumendjel A,Peuchmaur M,Andrieu T,Falson P

    更新日期:2018-06-01 00:00:00

  • Selective and potent small-molecule inhibitors of PI3Ks.

    abstract::Class I PI3Ks are composed of four catalytic subunit variants (p110α, p110β, p110δ and p110γ). The PI3K pathway is among the most frequently activated pathways in many diseases, and has emerged as an attractive target for drug development, in particular for the treatment of many human cancers including breast, prostat...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.14.28

    authors: Jeong Y,Kwon D,Hong S

    更新日期:2014-05-01 00:00:00

  • A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.

    abstract::The EGFR is one of the most popular targets for anticancer therapies and many drugs, such as erlotinib and gefitinib, have got enormous success in clinical treatments of cancer in past decade. However, the efficacy of these agents is often limited because of the quick emergence of drug resistance. Fundamental structur...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0222

    authors: Guan H,Du Y,Ning Y,Cao X

    更新日期:2017-05-01 00:00:00

  • Structure-activity relationship of natural and synthetic coumarin derivatives against Mycobacterium tuberculosis.

    abstract::Aim: Eight coumarin derivatives (1a-h) obtained from natural (-)-mammea A/BB (1) and 13 synthetic coumarins (2-14) had their cytotoxicity and biological activity evaluated against Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates. Materials & methods: Anti-M. tuberculosis acti...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0281

    authors: Pires CT,Scodro RB,Cortez DA,Brenzan MA,Siqueira VL,Caleffi-Ferracioli KR,Vieira LC,Monteiro JL,Corrêa AG,Cardoso RF

    更新日期:2020-09-01 00:00:00

  • An unexpected discovery toward novel membrane active sulfonyl thiazoles as potential MRSA DNA intercalators.

    abstract::Aim: With the increasing emergence of drug-resistant bacteria, the need for new antimicrobial agents has become extremely urgent. This work was to develop sulfonyl thiazoles as potential antibacterial agents. Results & methodology: Novel hybrids of sulfonyl thiazoles were developed from commercial acetanilide and acet...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0303

    authors: Hu YY,Wang J,Li TJ,Yadav Bheemanaboina RR,Ansari MF,Cheng Y,Zhou CH

    更新日期:2020-10-01 00:00:00

  • Design and in vitro evaluation of a novel polymeric excipient for buccal applications.

    abstract:BACKGROUND:The objective of this study was to develop and evaluate a more effective mucoadhesive thiomer for buccal drug-delivery systems. METHODS:2-iminothiolane was covalently attached to a chitosan backbone. A preactivation step followed, mediated by 6,6´dithionicotinamide, thiol groups were modified by disulfide b...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.33

    authors: Laffleur F,Shahnaz G,Islambulchilar Z,Bernkop-Schnürch A

    更新日期:2013-04-01 00:00:00